Compliance and Market Status - Biophytis has regained compliance with the Nasdaq Global Select Market minimum bid price requirement, with the closing bid price of its American Depositary Shares at $1.00 or greater for the last 10 consecutive business days from March 30, 2023 to April 13, 2023[7]. - The notification from Nasdaq was received on April 14, 2022, indicating the company's compliance status[6]. Product Development and Clinical Trials - The company is developing Sarconeos (BIO101) as a treatment for sarcopenia, currently in a Phase 2 clinical trial in the United States and Europe[2]. - Sarconeos (BIO101) has shown positive results in a Phase 2-3 study for severe COVID-19 patients, with results released in Q1 2023[2]. - A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD)[2]. Company Focus and Operations - Biophytis is focused on therapeutics aimed at slowing degenerative processes associated with aging and improving functional outcomes for patients with age-related diseases[2]. - The company is based in Paris, France, and Cambridge, Massachusetts, with its ordinary shares listed on Euronext Growth and ADSs on Nasdaq Capital Market[2]. Forward-Looking Statements - The company considers its forward-looking statements to be based on reasonable assumptions, but acknowledges various risks and uncertainties that could affect actual outcomes[8]. - Biophytis has no obligation to publicly update or review any forward-looking statements except as required by law[8]. Investor Relations - The company’s contact for investor relations is Philippe Rousseau, CFO, available via email for inquiries[10].
Biophytis(BPTS) - 2022 Q4 - Annual Report